Assenagon Asset Management S.A. Sells 70,885 Shares of AMNEAL PHARMACEUTICALS, INC. $AMRX

Assenagon Asset Management S.A. lowered its holdings in AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX) by 8.6% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 748,851 shares of the company’s stock after selling 70,885 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.24% of AMNEAL PHARMACEUTICALS worth $6,058,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in AMNEAL PHARMACEUTICALS by 6.2% in the 1st quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company’s stock worth $132,092,000 after buying an additional 920,758 shares during the period. Nantahala Capital Management LLC lifted its holdings in AMNEAL PHARMACEUTICALS by 3.9% in the 1st quarter. Nantahala Capital Management LLC now owns 3,808,561 shares of the company’s stock worth $31,916,000 after buying an additional 143,032 shares during the period. BlackBarn Capital Partners LP lifted its holdings in AMNEAL PHARMACEUTICALS by 1.1% in the 1st quarter. BlackBarn Capital Partners LP now owns 2,881,654 shares of the company’s stock worth $24,148,000 after buying an additional 31,654 shares during the period. Acadian Asset Management LLC lifted its holdings in AMNEAL PHARMACEUTICALS by 51.3% in the 1st quarter. Acadian Asset Management LLC now owns 2,598,294 shares of the company’s stock worth $21,759,000 after buying an additional 880,471 shares during the period. Finally, Nuveen LLC purchased a new stake in AMNEAL PHARMACEUTICALS in the 1st quarter worth approximately $19,581,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. The Goldman Sachs Group assumed coverage on AMNEAL PHARMACEUTICALS in a report on Friday, June 6th. They issued a “buy” rating and a $12.00 price objective for the company. JPMorgan Chase & Co. increased their price objective on AMNEAL PHARMACEUTICALS from $12.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, September 16th. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $12.00.

AMNEAL PHARMACEUTICALS Price Performance

Shares of AMRX opened at $9.84 on Wednesday. AMNEAL PHARMACEUTICALS, INC. has a one year low of $6.68 and a one year high of $10.34. The firm has a market capitalization of $3.09 billion, a P/E ratio of 984.98 and a beta of 1.19. The business has a fifty day moving average of $9.03 and a 200 day moving average of $8.24.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a negative return on equity of 189.49% and a net margin of 0.12%. AMNEAL PHARMACEUTICALS has set its FY 2025 guidance at 0.700-0.750 EPS. Analysts expect that AMNEAL PHARMACEUTICALS, INC. will post 0.53 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Jason B. Daly sold 22,000 shares of AMNEAL PHARMACEUTICALS stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $9.05, for a total transaction of $199,100.00. Following the transaction, the executive vice president directly owned 10,606 shares in the company, valued at approximately $95,984.30. The trade was a 67.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Nikita Shah sold 114,492 shares of AMNEAL PHARMACEUTICALS stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $9.66, for a total value of $1,105,992.72. Following the transaction, the executive vice president owned 152,743 shares in the company, valued at $1,475,497.38. This trade represents a 42.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 609,206 shares of company stock valued at $5,700,625 over the last three months. 17.45% of the stock is currently owned by company insiders.

AMNEAL PHARMACEUTICALS Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.